Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German study condemns improper use of anti-decubitus mattresses:

This article was originally published in Clinica

Executive Summary

The improper use of anti-decubitus mattresses in is actually contributing the rise in decubitus incidence in Germany, says Ute Pilzecker, director of the medical care insurance division of the sickness funds' medical service in Schleswig Holstein. An examination of 554 care homes in Schleswig-Holstein last year revealed that the likelihood of patients getting decubitus ulcers addressed was high in only half of those surveyed. Staff were simply not aware of how to treat these ulcers and in only 20% of cases were sufficient measures taken to prevent them. In one particular case a patient weighing 35 kilos was placed on an anti-decubitus alternating system pressure mattress adjusted to accommodate 80 kilos. The hardness of the mattress thus caused the decubitus ulcer.

You may also be interested in...



Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine

As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.

Public Health Threat For EU Patients If IVDR Implementation Issues Remain Unaddressed

The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.

Topics

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel